Louvain-la-Neuve (Belgium), June 2, 2013 — IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, is pleased to announce that today 60 radiation therapy leaders travelled to Belgium to discover the first Proteus®ONE in factory.

IBA’s new, compact and affordable proton therapy solution, ProteusONE, includes a compact gantry and compact synchrocyclotron. It allows much greater access to Proton Therapy (PT) given the system is easier to install and operate and is also more easily financeable. ProteusONE’s unrivalled clinical capabilities make it the safest path to compact Intensity Modulated Proton Therapy (IMPT).

Olivier Legrain, Chief Executive Officer of IBA, said: “This visit and the quality of the participants underlines the significant interest that the worldwide radiation therapy community takes in proton therapy and the advances IBA is making. ProteusONE represents a solution to further reduce the costs and complexity of proton therapy, helping to lower the technological and financial risks for our stakeholders. Today, we have demonstrated that IBA’s extensive experience in developing proton therapy solutions and world leading technology makes IBA the best choice in the market today. With ProteusONE, proton therapy becomes an achievable reality for more patients worldwide.”

IBA’s revolutionary technologies are combined with more than 20 year’s experience of Proteus® technology to form the most advanced compact Intensity Modulated Proton Therapy (IMPT) system in the world.

The first patient’s to benefit from IBA’s ProteusONE technology are expected to be treated in 2014 at Willis Knighton Cancer Center (WKCC), Shreveport, Louisiana, USA.

The IBA Proteus technology is today planned or utilized in 25 centers around the world, 15 are treating patients every day.

About Proteus®ONE

IBA ProteusONE is the safest way compact Intensity Modulated Proton Therapy (IMPT). It encompasses the latest technologies of Proteus®PLUS, which have been developed with top clinical institutions worldwide.

This solution offers IMPT powered by Pencil Beam Scanning (PBS) and 3D Cone-beam Computed Tomography (3D CBCT). It enables physicians to leverage completely on the clinical effectiveness of ProtonTherapy. ProteusONE has been inspired by everyday clinical practice. Its design, developed in collaboration with Philips enhances the patient and staff experience by fostering a soothing environment making therapy safer and easier. www.iba-proteusone.com

About Proton Therapy
Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and sparing healthy surrounding tissue.

IBA is the only supplier to have multiple centers treating cancer patients with Pencil Beam Scanning (PBS), the most precise form of proton therapy. PBS enables Intensity Modulated Proton Therapy (IMPT), allowing clinicians to precisely target a cancerous tumor by controlling both the intensity and the spatial distribution of the dose to the millimeter.

As access to proton therapy increases in Europe and across the world, IBA continues to demonstrate compassionate innovations with more patient-friendly treatment rooms and more precise therapies. IBA proton therapy systems account for more than half of the world’s clinically based proton therapy facilities. To date they include 15 operational proton therapy centers worldwide, and 10 more centers in development. More info on www.iba-protontherapy.com

About IBA
IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company’s expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA’s leading fully integrated IntegraLab® radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com